A simple screening assay for certain fibrinolysis parameters (FIPA)

Thrombosis Research

Volumn 97, Issue 4, 2000, Pages 231-237

  Stief, Thomas W ^a   Hinz, Frauke ^a   Kurz, Jürgen ^a   Doss, Manfred O ^a   Kretschmer, Volker ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Assay; Fibrinolysis; Plasma; Urokinase

Indexed keywords

ALPHA 2 ANTIPLASMIN; APROTININ; HEPARIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANEXAMIC ACID; UROKINASE;

ARTICLE; ASSAY; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; LABORATORY TEST; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SCREENING TEST;

ADOLESCENT; ADULT; AGED; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MIDDLE AGED; QUALITY CONTROL; REFERENCE VALUES; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033964879     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00165-6     Document Type: Article

References (24)

1. von Kaulla E., von Kaulla K.N. Detection of hypercoagulability states by a modified ethanol gelation test and its correlation with other coagulation procedures. Am J Clin Pathol. 61:1974;810-822.
2. Jespersen J., Astrup T. A study of the fibrin plate assay for fibrinolytic agents. Optimal conditions, reproducibility and precision. Haemostasis. 13:1983;301-315.
3. Fareed J., Hoppensteadt D.A., Leya F., Iqbal O., Wolf H., Bick R. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem. 44:1998;1845-1853.
4. Bachmann F. The plasminogen-plasmin enzyme system. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and thrombosis. Basic principles and clinical practice 3rd ed:1994;1592-1622 Lippincott, Philadelphia.
5. van Giezen J.J., Chung A., Hing J.E., Vegter C.B., Bouma N.N., Jansen J.W. Fibrinolytic activity in blood is distributed over a cellular and the plasma fraction which can be modulated separately. Thromb Haemost. 72:1994;887-892.
6. Amiral J., Malmejac A., Gin H., Pannell R., Vissac A.-M., Seigneur M., Scarabin P.-Y., Boisseau M., Guize L., Gurewich V. Evaluation of the fibrinolytic potential on plasma:physiological and pathological variations, and associations with cardio-vascular disease risk factors. Fibrinol Proteolysis. 13(Suppl 1):1999;1-10.
7. Stief T.W., Lenz P., Becker U., Heimburger N. Determination of plasminogen activator (PAI) capacity of human plasma in presence of oxidants. A novel principle Thromb Res. 50:1988;559-573.
8. Chmielewska J., Ranby M., Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator. Thromb Res. 31:1983;427-436.
9. Rosen S., Wejkum L., Billing-Claeson S., Ghosh R., Grdic K., Chmielewska J., Meijer P., Kluft C., Tengborn L., Conkie J., Walker I. Evaluation of a bioimmuno assay for t-PA activity and its relation to PAI-1 activity and antigen levels. Fibrinol Proteolysis. 12:1998;340-346.
10. Clemmensen I. Inhibition of urokinase by complex formation with human antithrombin III in absence and presence of heparin. Thromb Haemostas. 39:1978;616-623.
11. Stief T.W., Martin E., Villalobos E., Yoldi F., Rodriguez J.M. Specificity of functional determination of urokinase in human plasma using selective oxidants. Fibrinolysis. 4(Suppl 2):1990;148-149.
12. Nesheim M.E. Tafi. Fibrinol Proteolysis. 13:1999;72-77.
13. Kettle P., Mayne E. A bleeding disorder due to deficiency of alpha 2-antiplasmin. J Clin Pathol. 38:1985;428-429.
14. Kordich L., Feldman L., Porterie P., Lago O. Severe hemorrhagic tendency in heterozygous alpha 2-antiplasmin deficiency. Thromb Res. 40:1985;645-651.
15. Knot E.A., ten Cate J.W., Lamping R.J., Gie L.K. Alpha 2-antiplasmin. Functional characterization and metabolism in a heterozygote deficient patient Thromb Haemost. 55:1986;375-378.
16. Holmes W.E., Lijnen H.R., Nelles L., Kluft C., Nieuwenhuis H.R., Rijken D.C., Collen C. Alpha 2-antiplasmin Enschede. Alanine insertion and abolition of plasmin inhibitory activity Science. 238:1987;209-211.
17. Kluft C., Nieuwenhuis H.R., Rijken D.C., Groeneveld E., Wijngaards G., van Berkel W., Dooijewaard G., Sixma J.J. AP Enschede. Dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder J Clin Invest. 80:1987;1391-1400.
18. Williams E.C. Plasma alpha 2-antiplasmin activity. Role in evaluation and management of fibrinolytic states and other bleeding disorders. Arch Intern Med. 149:1989;1769-1772.
19. Schleef R.R., Higgins D.L., Pillemer E., Levitt L.J. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest. 83:1989;1747-1752.
20. Dieval J., Nguyen G., Gross S., Delobel J., Kruithof E.K. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood. 77:1991;528-532.
21. Reilly T.M., Mousa S.A., Seetharam R., Racanelli A.L. Recombinant plasminogen activator inhibitor type 1. A review of structural, functional, and biological aspects Blood Coagul Fibrinol. 5:1994;73-81.
22. Lee M.H., Vosburgh E., Anderson K., McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood. 81:1993;2357-2362.
23. Fay W.P., Parker A.C., Condrey R., Shapiro D. Human plasminogen activator inhibitor-1 (PAI-1) deficiency. Characterization of a large kindred with a null mutation in the PAI-1 gene Blood. 90:1997;204-208.
24. Carmeliet P., Stassen J.M., Schoonjans L., Ream B., van den Oord J.J., De Mol M., Mulligan R.C., Collen D. Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest. 92:1993;2756-2760.